Haisco Pharmaceutical Group Co., Ltd. Drug Pipeline

Haisco Pharmaceutical Group Co., Ltd. maintains a substantial clinical development portfolio, with 90 trials registered since 2008, including 36 currently active studies. These active programs span from Phase 1 through Phase 4, with the largest number of assets in Phase 2 (17 trials), followed by Phase 1 (11 trials), Phase 3 (7 trials), and Phase 4 (1 trial). Haisco’s research activity covers seven therapeutic areas, with a notable concentration in respiratory medicine, which accounts for 22% of active programs (8 trials). Within respiratory, the leading indications are COPD and Idiopathic Pulmonary Fibrosis, each with 3 active trials; the Idiopathic Pulmonary Fibrosis programs include 2 in Phase 3. Oncology (5 active trials) and Immunology (4 active trials) represent the next most active areas, followed by Pain (3 active trials). The portfolio's weighting toward earlier-phase trials suggests a focus on longer-term development rather than near-term market catalysts.